Entacapone / Tolcapone

Mechanism

Chemical and Commercial Profile

Common trade names: Comtess, Tasmar, Stalevo (co-formulated with levodopa/carbidopa).
Group: Antiparkinsonian, selective inhibitors of the enzyme catechol-O-methyltransferase (COMT).

Mechanism of Action

Entacapone and tolcapone act by selectively and reversibly blocking the enzyme catechol-O-methyltransferase (COMT). In the absence of COMT inhibitors, levodopa administered with carbidopa is diverted peripherally toward the O-methylation pathway, generating the metabolite 3-O-methyldopa (3-OMD), which competes with levodopa for the LAT-1 transporter to cross the BBB.

Entacapone (Selective Peripheral Action)

Entacapone does not cross the blood-brain barrier; it acts exclusively in peripheral tissues by blocking the conversion of levodopa to 3-OMD. This increases the area under the curve (AUC) of plasma levodopa by 35% and reduces end-of-dose symptoms.

Tolcapone (Central and Peripheral Dual Action)

Tolcapone is a high-affinity lipophilic inhibitor that easily crosses the BBB, inhibiting COMT centrally and peripherally. This optimizes dopamine retention in the striatum, with superior potency and efficacy but with a toxicity profile that limits its use.

Pharmacokinetics

Pharmacokinetics

• Absorption: Rapid after oral intake; the bioavailability of entacapone is 35%, while that of tolcapone is 65%. The plasma peak is reached 1-2 hours after taking.
• Distribution: Very high binding to plasma proteins (>98%), mainly to serum albumin. The volume of distribution is 0.3 L/kg. It crosses the blood-brain barrier with difficulty (entacapone) or easily (tolcapone).
• Metabolism: Hepatic through direct glucuronidation mediated by the enzyme UGT1A9. It does not present interactions with the cytochrome system.
• Excretion: Biliary/fecal (90%) and renal (10%) mainly in the form of inactive conjugated metabolites.
• Half-life (t_1/2): Plasma short of 1.5-2 hours (entacapone); 2.5-3 hours (tolcapone). Requires sequential administration.

Indicators and dose

Indications

• Adjuvant treatment of advanced Idiopathic Parkinson's Disease with motor fluctuations ("wearing-off"), in mandatory combination with levodopa/carbidopa or levodopa/benserazide.

Dosage and Settings

• Entacapone (Comtess): Administer one 200 mg tablet concurrently with each dose of levodopa/carbidopa, up to a maximum of 10 tablets per day (2000 mg/day total).
• Tolcapone (Tasmar): 100-200 mg three times a day (separate from food). If no clinical response is observed after 3 weeks, treatment should be suspended preventively.
• Liver Failure: Absolute contraindication for tolcapone. Entacapone should be avoided in Child-Pugh B or C cirrhosis due to lack of cumulative data.
• Renal Failure: It does not require special dose adjustments, but caution is recommended in hemodialysis due to low renal elimination.

Security

Contraindications

• Acute or chronic active liver disease (absolute contraindication for tolcapone).
• History of Neuroleptic Malignant Syndrome (NMS) or drug-induced rhabdomyolysis.
• Pheochromocytoma or catecholamine-secreting tumors.

Adverse Effects (ADR)

Fulminant Hepatotoxicity Alert (Tolcapone)

Tolcapone is associated with a serious risk of inducing severe acute hepatotoxicity of an idiosyncratic type and fatal fulminant hepatic failure (occurring in 1% of exposed patients, usually in the first 6 months of treatment). Its regimen is legally restricted in Spain as a drug of last choice, requiring informed consent from the patient and **mandatory determination of transaminases (ALT/AST) every 2 weeks** during the first year of treatment.

• Gastrointestinal: Persistent late-onset diarrhea (occurs in 10% of patients due to peripheral cholinergic motility changes), nausea of central dopaminergic origin, vomiting, orange urinary discoloration (harmless effect derived from the chromogenic excretion of entacapone metabolites).
• Dopaminergic (CNS): Transient exacerbation of peak dose dyskinesias (requires reducing the dose of levodopa by 10-20% at the beginning), visual hallucinations, confusion, orthostatic hypotension.

Clinical Interactions

• Non-selective MAOIs: Co-administration is prohibited due to the risk of hypertensive crisis due to dual inhibition of catecholamine catabolism.
• Drugs metabolized by COMT: Isoprenaline, adrenaline and dobutamine can increase their concentrations and cause sinus tachycardia if associated with COMT inhibitors.

Pregnancy and Breastfeeding

FDA Category: C. Very limited human data; it is absolutely not recommended during pregnancy due to systemic ophthalmic restriction. Breastfeeding: Relatively contraindicated; its direct milk excretion is unknown, but dopamine inhibition can reflexively depress lactation.